A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data …
R Rajendram, S Fraser-Bell, A Kaines… - Archives of …, 2012 - jamanetwork.com
Objective To report the 2-year outcomes of the BOLT study, a prospective randomized
controlled trial evaluating intravitreous bevacizumab and modified Early Treatment Diabetic
Retinopathy Study (ETDRS) macular laser therapy (MLT) in patients with persistent clinically
significant macular edema (CSME). Methods In a 2-year, single-center, randomized
controlled trial, 80 patients with center-involving CSME and visual acuity of 20/40 to 20/320
were randomized to receive either bevacizumab or MLT. Main Outcome Measures Primary …
controlled trial evaluating intravitreous bevacizumab and modified Early Treatment Diabetic
Retinopathy Study (ETDRS) macular laser therapy (MLT) in patients with persistent clinically
significant macular edema (CSME). Methods In a 2-year, single-center, randomized
controlled trial, 80 patients with center-involving CSME and visual acuity of 20/40 to 20/320
were randomized to receive either bevacizumab or MLT. Main Outcome Measures Primary …
以上显示的是最相近的搜索结果。 查看全部搜索结果